Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Colorectal cancer

Epiregulin (EREG)

In vitro and mouse studies suggest inhibiting EREG could help treat colitis-associated colorectal cancer. EREG expression was upregulated in tumor tissues from patients and mice with colitis-associated colorectal cancer but not in tissues from those with spontaneous colorectal cancer. In a mouse model for colitis-associated cancer, Ereg knockout decreased tumor growth compared with no knockout. Next steps could include developing pharmacological inhibitors of EREG.

SciBX 6(12); doi:10.1038/scibx.2013.285
Published online March 28, 2013

Patent and licensing status unavailable

Neufert, C. et al. J. Clin. Invest.; published online March 15, 2013;
doi:10.1172/JCI63748
Contact: Clemens Neufert, University of Erlangen-Nuremberg, Erlangen, Germany
e-mail:

clemens.neufert@uk-erlangen.de